Literature DB >> 30838966

Reduction in antimicrobial use among medical intensive care unit patients during a cluster randomized crossover trial of palliative care consultation.

Jason P Burnham1, Stephen Chi2, Jessica Ma3, Maria C Dans4, Marin H Kollef5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30838966      PMCID： PMC6605046          DOI： 10.1017/ice.2019.34

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


× No keyword cloud information.
  5 in total

1.  Antimicrobial use at the end of life among hospitalized patients with advanced cancer.

Authors:  Andrew J Thompson; Maria J Silveira; Caroline A Vitale; Preeti N Malani
Journal:  Am J Hosp Palliat Care       Date:  2012-01-04       Impact factor: 2.500

2.  Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually.

Authors:  Kenneth E Thorpe; Peter Joski; Kenton J Johnston
Journal:  Health Aff (Millwood)       Date:  2018-03-21       Impact factor: 6.301

Review 3.  Antimicrobial use for symptom management in patients receiving hospice and palliative care: a systematic review.

Authors:  Joseph H Rosenberg; Jennifer S Albrecht; Erik K Fromme; Brie N Noble; Jessina C McGregor; Angela C Comer; Jon P Furuno
Journal:  J Palliat Med       Date:  2013-10-23       Impact factor: 2.947

4.  Symptomatic treatment of infections in patients with advanced cancer receiving hospice care.

Authors:  Raquel E Reinbolt; Allison M Shenk; Patrick H White; Rudolph M Navari
Journal:  J Pain Symptom Manage       Date:  2005-08       Impact factor: 3.612

5.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.